May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin) as an Adjuvant to Vitrectomy With Silicone Oil Tamponade in Severe Proliferative Diabetic Retinopathy (PDR): Anatomic and Visual Outcomes
Author Affiliations & Notes
  • L. M. Suarez Tata
    Service Vitreous-Retina, Clinica Oftalmologica el Vinedo, Valencia, Venezuela
  • M. Suarez-Tata
    Service Vitreous-Retina, Clinica Oftalmologica el Vinedo, Valencia, Venezuela
  • J. L. Guerrero-Naranjo
    Service Vitreous-Retina, Hospital para Prevenir la Ceguera Luis Sanchez Bulnes, Mexico City, Mexico
  • J. Sanchez
    Service Vitreous-Retina, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • J. Arevalo
    Service Vitreous-Retina, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • Footnotes
    Commercial Relationships L.M. Suarez Tata, None; M. Suarez-Tata, None; J.L. Guerrero-Naranjo, None; J. Sanchez, None; J. Arevalo, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5040. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. M. Suarez Tata, M. Suarez-Tata, J. L. Guerrero-Naranjo, J. Sanchez, J. Arevalo; Intravitreal Bevacizumab (Avastin) as an Adjuvant to Vitrectomy With Silicone Oil Tamponade in Severe Proliferative Diabetic Retinopathy (PDR): Anatomic and Visual Outcomes. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5040.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To describe and analyze the anatomic findings, complications, and visual outcomes in patients after intravitreal (IVT) bevacizumab (Avastin) as an adjuvant to pars plana vitrectomy (PPV) with silicone oil (SO) tamponade in severe proliferative diabetic retinopathy (PDR).

Methods:: Prospective, non-comparative, interventional study. Eleven eyes of 9 patients (mean age: 50.2 years; range: 35 to 72 years) with severe PDR characterized by fibrovascular proliferation, preretinal and/or vitreous hemorrhage, and tractional retinal detachment involving or not the macula participated in this study. The study was approved by an Institutional Review Board. All patients signed an informed consent and were operated on after IVT bevacizumab (2.5 mg) as an adjuvant to PPV several days (mean: 26 days; range: 7 to 120 days) before surgery and immediately after fluid-air exchange. Complete ophthalmologic evaluation was performed before and after surgery. Best-corrected visual acuity (BCVA) measurements were made using ETDRS charts on baseline and at days 1, 4, 7, 15, 30, 60 and 90 after vitrectomy. SO tamponade was used in all cases. Statistical analysis was performed utilizing a Student t-test.

Results:: Anatomical success was obtained in 100% cases with complete reattachment of the retina with a minimum follow-up of 3 months (mean: 4.2 months; range: 3.5 to 6 months). The mean baseline best-correct visual acuity (BCVA) was LogMAR = 1.8 (range: 1 to 2.3). Final mean BCVA after surgery was LogMAR = 0.96 (range: 0 to 2.3) (p < 0.0001). BCVA improved three or more ETDRS lines (doubling of the visual angle) in nine eyes (81.8%) and there was no change in two eye 18.2%). None of the eyes lost BCVA after the procedure. No ocular or systemic adverse events have been observed.

Conclusions:: Successful anatomic and visual outcomes at 3 months suggest that using IVT injection of bevacizumab several weeks before surgery, and after PPV with SO can be very useful in the management of severe PDR. IVT bevacizumab provided reduction of retinal and iris neovascularization, facilitated the surgical procedure, reduced the risk of intraoperative bleeding, and resulted in improvement or stability of BCVA in all eyes. Further studies and longer follow up are needed to confirm our findings.

Keywords: diabetic retinopathy • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×